← All trials
NCT05540184
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2022
- Primary completion
- Sep 30, 2025
- Completion date
- Sep 30, 2025
- First posted
- Sep 14, 2022
- Last posted
- Sep 15, 2022
- Enrollment
- 124
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beni Suef UniversityLead sponsor
- Beni Suef UniversityReponsible party - principal investigator
- Cairo UniversityCollaborator
- Beni Suef UniversityStudy chair
- Beni Suef UniversityStudy director
- Cairo UniversityOverall official - principal investigator
- Cairo UniversityOverall official - principal investigator
- Beni Suef UniversitySponsor investigator
- Cairo UniversityOfficial
- Cairo UniversityOfficial
- Beni Suef UniversityOfficial
- Beni Suef UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.